SABCS 2024: Disitamab Vedotin Demonstrates Clinically Meaningful Results in the Treatment of HER2-Positive Advanced Breast Cancer with Liver Metastasis
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: A RemeGen-sponsored, randomized, open-label, multicenter phase 3 study comparing the efficacy and safety of disitamab vedotin versus treatment with the tyrosine kinase inhibitor lapatinib + capecitabine in patients with HER2-positive advanced breast cancer with liver metastasis.
Author: Peter Hofland
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4405917934